GLYC — GlycoMimetics Share Price
0.000.00%
Last trade - 00:00- $124.07m
- $82.27m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.23 | ||
| Price to Tang. Book | 3.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12,406.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -102.06% | ||
| Return on Equity | -90.72% | ||
| Operating Margin | -392752.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 10.16 | 1.16 | 0.07 | 0.01 | n/a | 28.74 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Directors
- Timothy Pearson NEC (53)
- Harout Semerjian CEO (50)
- John Magnani CFD (68)
- Brian Hahn CFO (46)
- Eric Feldman SVP (65)
- Armand Girard SVP (52)
- Rachel King DRC (61)
- Patricia Andrews IND (63)
- Mark Goldberg IND (67)
- Scott Jackson IND (56)
- Daniel Junius IND (68)
- Scott Koenig IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 4th, 2003
- Public Since
- January 10th, 2014
- No. of Shareholders
- 21
- No. of Employees
- 35
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 64,450,385
- Address
- 9708 Medical Center Drive, ROCKVILLE, 20850
- Web
- https://glycomimetics.com/
- Phone
- +1 2402431201
- Auditors
- Ernst & Young LLP
Upcoming Events for GLYC
Q1 2024 GlycoMimetics Inc Earnings Release
GlycoMimetics Inc Annual Shareholders Meeting
Q2 2024 GlycoMimetics Inc Earnings Release
Similar to GLYC
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the GlycoMimetics share price?
As of Today at 19:09 UTC, shares in GlycoMimetics are trading at $1.93. This share price information is delayed by 15 minutes.
How has the GlycoMimetics share price performed this year?
Shares in GlycoMimetics last closed at $1.93 and the price had moved by +30.95% over the past 365 days. In terms of relative price strength the GlycoMimetics share price has outperformed the S&P500 Index by +8.97% over the past year.
What are the analyst and broker recommendations for GlycoMimetics?
The overall consensus recommendation for GlycoMimetics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the GlycoMimetics dividend yield?
GlycoMimetics does not currently pay a dividend.
Does GlycoMimetics pay a dividend?
GlycoMimetics does not currently pay a dividend.
When does GlycoMimetics next pay dividends?
GlycoMimetics does not currently pay a dividend.
How do I buy GlycoMimetics shares?
To buy shares in GlycoMimetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GlycoMimetics?
As of the previous close price of $1.93, shares in GlycoMimetics had a market capitalisation of $124.07m.
Where are GlycoMimetics shares listed?
Here are the trading details for GlycoMimetics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GLYC
What kind of share is GlycoMimetics?
Based on an overall assessment of its quality, value and momentum GlycoMimetics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GlycoMimetics share price forecast for 2024?
The analyst consensus target price for shares in GlycoMimetics is $7.00. That is 263.64% above the last closing price of $1.93.
Analysts covering GlycoMimetics currently have a consensus Earnings Per Share (EPS) forecast of -$0.61 for the next financial year.
What is the trend in the GlycoMimetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlycoMimetics. Over the past six months, its share price has outperformed the S&P500 Index by +29.7%.
As of the last closing price of $1.93, shares in GlycoMimetics were trading -6.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GlycoMimetics PE Ratio?
The GlycoMimetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GlycoMimetics?
GlycoMimetics' management team is headed by:
- Timothy Pearson - NEC
- Harout Semerjian - CEO
- John Magnani - CFD
- Brian Hahn - CFO
- Eric Feldman - SVP
- Armand Girard - SVP
- Rachel King - DRC
- Patricia Andrews - IND
- Mark Goldberg - IND
- Scott Jackson - IND
- Daniel Junius - IND
- Scott Koenig - IND